Saxagliptin for type 2 diabetes

Article, Review English OPEN
Chacra, Antonio R;

Antonio R Chacra, MDDiabetes Center, Federal University of São Paulo, BrazilAbstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in patients with type 2... View more
  • References (46)
    46 references, page 1 of 5

    1. Onglyza [package insert]. Princeton, NJ/Wilmington, DE: BristolMyers Squibb Company/AstraZeneca Pharmaceuticals LP; Jul 2009.

    2. Januvia [package insert]. Whitehouse Station, NJ: Merck and Co., Inc.; Feb 2010.

    3. Galvus [European Public Assessment Report]. West Sussex, UK: Novartis Europharm Limited. Available from: http://www.ema.europa. eu/humandocs/Humans/EPAR/galvus/galvus.htm. Accessed Jun 8, 2010.

    4. Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48(15):5025-5037.

    5. Fura A, Khanna A, Vyas V, et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos. 2009;37(6):1164-1171.

    6. Rosenstock J,Aguilar-Salinas C, Klein E; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401-2411.

    7. Jadzinsky M, Pfützner A, Paz-Pacheco E; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611-622.

    8. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(5):376-386.

    9. DeFronzo RA, Hissa M, Garber AJ, et al; Saxagliptin 014 Study Group. The efcfiacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009;32(9):1649-1655.

    10. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial. Int J Clin Pract. 2009;63(9):1395-1406.

  • Related Research Results (1)
  • Similar Research Results (1)
    Saxagliptin for type 2 diabetes (2010)
  • Related Organizations (2)
  • Metrics
Share - Bookmark